行情

XLRN

XLRN

Acceleron制药
NASDAQ

实时行情|Nasdaq Last Sale

92.85
+0.65
+0.71%
盘后: 92.85 0 0.00% 16:00 08/13 EDT
开盘
92.67
昨收
92.20
最高
93.94
最低
92.00
成交量
19.31万
成交额
--
52周最高
110.75
52周最低
37.60
市值
55.61亿
市盈率(TTM)
-35.7239
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测XLRN价格均价为126.67,最高价位137.00,最低价为89.00。

EPS

XLRN 新闻

更多
Acceleron Pharma EPS beats by $0.20, beats on revenue
Acceleron Pharma (NASDAQ:XLRN): Q2 GAAP EPS of -$0.34 beats by $0.20. Revenue of $39.8M (+43.8% Y/Y) beats by $9.72M. Press Release
seekingalpha · 08/07 01:23
Acceleron Pharma (XLRN) Reports Q2 Loss, Tops Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of 38.18% and 23.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 22:15
Acceleron Reports Second Quarter 2020 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial re
Business Wire · 08/06 20:01
Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt)
Business Wire · 08/06 11:10
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Acceleron Pharma Inc. - XLRN
New York, New York--(Newsfile Corp. - August 3, 2020) - Levi & Korsinsky announces it has commenced an investigation of Acceleron Pharma Inc. (NASDAQ: XLRN) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk
Newsfile · 08/03 14:14
Acceleron Pharma (XLRN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Acceleron (XLRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Acceleron Pharma (XLRN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Acceleron (XLRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/27 16:31
Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 6, 2020 at 5:00 p.m. EDT to discuss its second quarter 2020 operating and financial results.
Business Wire · 07/27 11:00

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

XLRN 简况

Acceleron Pharma Inc.是一家进行临床阶段研究的美国生物制药公司。该公司专注于探索、开发和商业化基于人体机制的候选药物和治疗方案(人体通过这些机制自动调节细胞和组织的生长和修复)。该公司的候选药物和治疗方案用于治疗严重和罕见疾病。该公司的候选药物包括Luspatercept、Sotatercept、Dalantercept、ACE-083、ACE-2494、ACE-1332、ACE-3891、ACE-2798、ACE-2536和ACE-2395。Luspatercept促进红细胞生成。该公司正在开发的Sotatercept用于治疗慢性肾脏疾病。Dalantercept通过抑制激活素受体样激酶(ALK)1受体的信号传导来抑制血管形成,从而达到治疗癌症的目的。ACE-083用于治疗局部肌肉疾病。ACE-2494旨在治疗全身性肌肉疾病。ACE-3891、ACE-1332、ACE-2798、ACE-2536和ACE-2395处于临床前开发阶段。
展开

微牛提供Acceleron Pharma Inc(NASDAQ-XLRN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的XLRN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易XLRN股票基本功能。